...EB66 cell culture technology licensed from Valneva SE (Euronext:VLA; VSE:VLA); (C) cell culture technology from SK Chemicals Co. Ltd....

...Sanofi's Sanofi Pasteur vaccines division and SK Chemicals partnered to co-develop a pneumococcal polysaccharide-protein conjugate vaccine. Sanofi...
...to provide details of the planned product, and SK could not be reached for details. SK Chemicals Co. Ltd....

...companies partnered to co-develop SK Biopharmaceuticals' YKP10811 to treat irritable bowel syndrome with constipation (IBS-C). SK Chemicals...
...Korea, where it will conduct late-stage Phase II and Phase III trials of the product. SK Chemicals...
...serotonin (5-HT4) receptor partial agonist is in a Phase II trial to treat chronic constipation. SK Chemicals...

...TheraVida granted SK Chemicals exclusive rights to develop and commercialize Tolenix ( THVD-201 ) and THVD-202 in...
...THVD-201 ) and THVD-202 in South Korea for overactive bladder (OAB) and urge urinary incontinence. SK Chemicals...
...first sale in South Korea, plus tiered, double-digit royalties. TheraVida declined to disclose details, and SK Chemicals...

...in Europe, Central America and Brazil. Endo markets frovatriptan as Frova in North America, while SK Chemicals Co. Ltd....

...in Europe, Central America and Brazil. Endo markets frovatriptan as Frova in North America, while SK Chemicals Co. Ltd....

...Teijin launched Feburic febuxostat in Japan and Korea to treat hyperuricemia. Partner SK Chemicals will market the...
...Osaka, Japan) markets febuxostat as Uloric in the U.S., where it has rights from Teijin SK Chemicals Co. Ltd....

...The companies signed a memorandum of understanding to develop and commercialize vaccines from SK Chemicals for undisclosed...
...using Xcellerex's FlexFactory biomanufacturing platform. Further terms were not disclosed. Xcellerex Inc. , Marlborough, Mass. SK Chemicals Co. Ltd....

...The approval triggers an undisclosed milestone payment to Vernalis from its South Korean marketing partner SK Chemicals Co. Ltd....

...cancer patients Ph III suspended to resolve dosing mechanism Akela (TSX:AKL)/Janssen Pharmaceutica subsidiary of J&J (NYSE:JNJ)/SK Chemicals/...